Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts.

During the past decade, Dana-Farber Cancer Institute and Mass General Hospital conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dana-Farber Cancer Institute and Mass General Hospital" are "Giant Cell Glioblastoma" (2 trials), "Glioblastoma" (2 trials), "Glioblastoma With Oligodendroglial Component" (2 trials), "Gliosarcoma" (2 trials) and "Small Cell Glioblastoma" (2 trials). Many other conditions were trialed in "Dana-Farber Cancer Institute and Mass General Hospital" in a lesser frequency.

Most popular intervention types in "Dana-Farber Cancer Institute and Mass General Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "KLH" (2 trials), "Rindopepimut (CDX-110) with GM-CSF" (2 trials), "Bevacizumab" (1 trials) and "Temozolomide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dana-Farber Cancer Institute and Mass General Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Dana-Farber Cancer Institute and Mass General Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Dana-Farber Cancer Institute and Mass General Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dana-Farber Cancer Institute and Mass General Hospital, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".